Company intelligence / Profile preview

Bioquark Inc.

Philadelphia, PA, USAprweb.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Bioquark’s lead program, BQ-A, is in development. It has demonstrated direct reprogramming and remodeling effects on diseased or damaged cells in living organisms by creating tissue-specific micro-environments for efficient regeneration and repair. These mimic those seen during normal human morphogenic development as well as amphibian limb regeneration. There are no published clinical trial results to date.

Therapeutic areas: Psychiatry
Modalities: biologicscombinatorial biologicsnatural biologic-based products
Industry: Biotech

Drug pipeline

1 asset

BQ-A peptide extract

Beyond the preview

Go deeper on Bioquark Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioquark Inc..

Explore the full profile